PepMix™Human(Cyclin-B1)ProductCode:PM-CYC_B1Poolof106peptidesderivedfromapeptidescan(15merswith11aaoverlap)throughG2/mitotic-specificcyclin-B1(Swiss-ProtID:P14635)ofHomosapiens(Human)forTcellassays(e.g.ELISPOT).Amount:1vialcontaining15nmol(appr.25µg)perpeptidePurity:>70%(HPLC-MS)DeliveryFormat:FreezedriedinambertypeglassvialApplication(s):T-cellassays,Immunemonitoring,AntigenspecificT-cellstimulation,T-cellexpansion,CellularimmuneresponseIndication(s)/Topic(s):CancerDeliveryTime:2-5daysPepMixes™PeptidePoolsTheuseofcompleteprotein-spanningmixturesofoverlappingpeptides(PepMix™)isextremelyefficientforimmunostimulationofT-lymphocytesanddiagnosticapplications.InordertoestablishreliableandvalidatedT-cellassayssuchasELISPOT,appropriatepositiveandnegativecontrolsareessential.SelectionofsuchcontrolshelpstoconfirmproperfunctionalityoftheassayaswellasviABIlityofthecellsused.Inaddition,highqualitycontrolsaremostimportanttoestablishstandardizedassayprotocolsinclinicalsetups.Comparedtocommonlyusedcontrolslikephytohemagglutinin(PHA)andconcanavalinA(ConA)thatstimulateT-cellsaswellasothercelltypesorfulllengthantigens,syntheticpeptidepoolsoffertheadvantageofahighbatch-to-batchreproducibility,applicabilityofreliablechemicalandbiochemicalQC/QAmeasuresandshelfstabilitywhenstoredasfreezedriedaliquots.BenefitsofPepMix™-EquivalentorbetterstimulationofCD4+andCD8+T-cellresponsescomparedtowholeproteinantigens-SimultaneousdetectionofCD4+andCD8+responsesinasinglesample-ImprovedresponsesinstoredbloodandPBMcellscomparedtowholeproteinantigens-Morereliableascontrolthanphytohemagglutinin(PHA)andconcanavalinA(ConA)-High-batch-to-batchreproducibility-Reliablechemicalandbiochemicalqualitycontrolandqualityassuranceforpeptidesynthesisandpeptidepoolgeneration-ProlongedshelfstabilitywhenstoredfreezedriedPepMix™Human(Cyclin-B1)SelectedReferences"DysfunctionofPSA-specificCD8+TCellsinProstateCancerPatientsCorrelateswithCD38andTim-3Expression"Jappetal.,CancerImmunolImmunother.(2015)-PMID:26289091"AnHPV-E6/E7ImmunotherapyPlusPD-1CheckpointInhibitionResultsinTumorRegressionandReductioninPD-L1Expression"Riceetal.,CancerGeneTherapy(2015)-PMID:26337747"Survivin-specificCD4+TCellsareDecreasedinPatientswithSurvivin-positiveMyeloma"Lockeetal.,JImmunotherCancer(2015)-PMID:25992291"APhaseITrialCombiningDecitabine/dendriticCellVaccineTargetingMAGE-A1,MAGE-A3andNY-ESO-1forChildrenwithRelapsedorTherapy-RefractoryNeuroblastomaandSarcoma"Krishnadasetal.,CancerImmunolImmunother.(2015)-PMID:26105625"GuidelinesFortheAutomatedEvaluationofElispotAssays"Janetzkietal.,NatureProtocols(2015)-PMID:26110715"PresenceofCirculatingHer-2-reactiveCD8+T-CellsisAssociatedwithLowerFrequenciesofMyeloid-derivedSuppressorCellsandRegulatoryTCells,andBetterSurvivalinElderlyBreastCancerPatients"KiniBailuretal.,BreastCancerResearch(2015)-PMID:n.a."STAT3SignalingContributestotheHighEffectorActivitiesofInterleukin-15-derivedDendriticCells"Okadaetal.,ImmunolCellBiol.(2015)-PMID:25582338ApplicationNotes"DevelopingMulti-HIVAntigenSpecificT-CellsasaComponentofaCureStrategy"Lametal.(2015)Fulltext"Peptide-stimulatedExpansionofVirus-specificTcellsForPreventativeTreatmentAfterAllogeneicStemCellTransplantation"Garyetal.(2015)FulltextTestimonials"Toestablishanovelroleformyeloidderivedsuppressorcells(Pallettetal,Nat.Med.2015)inchronicviralinfection,weutilisedthePepMixCEFPool(extended)aswellasacustomsynthesizedPepMixspanningthecoreregionofHBVgenotypeD.Whereas,theCEFpeptidepoolconsistsof32peptides,eachcorrespondingtoadefinedHLAclassI-restrictedT-cellepitopefromCytomegalo,Epstein-Barr,andInfluenzavirus,thelattercustomPepMixincluded15mericpeptidesoverlappingby10aminoacids.SpecificallythiscompositionenabledustomonitorboththeantiviralCD8+andCD4+TcellresponsesinchronicHBVinfectionandthenon-antigenspecificTcellsthatareknowntomediateimmunopathologyintheliver.OurentireexperiencewithJPT,fromordering/deliverytouseinthelabwasexcellent.Notonlywerethereagentsabletoperformreliablyandconsistentlyinvitrofrombatchtobatch,thecustomerandtechnicalsupportprovidedwascontinuallyavailableandefficientwhenneeded.JPTwillremainour"go-to"companyforpurchasingpeptides."Dr.LauraJPallett,InfectionandImmunity,UniversityCollegeLondon,UKPepMix™Human(Cyclin-B1)TechnicalData:ApplicationAntigenspecificT-cellstimulationCancerbioMarkerresearchImmunemonitoringT-cellassaysT-cellexpansionProteinNameG2/mitotic-specificcyclin-B1OrganismHomosapiens(Human)Indication/TopicCancerNumberofpeptides106 FurtherInformation:Amount1vialcontaining15nmol(appr.25µg)perpeptideSpecificationsPeptidescan(15merswith11aaoverlap)DocumentationProtocolandDatasheetSwiss-ProtIDP14635NCBINP_114172SequenceMALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRTALGDIGNKVSEQLQAKMPMKKEAKPSATGKVIDKKLPKPLEKVPMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPILVDTASPSPMETSGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIYAYLRQLEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKKMLQLVGVTAMFIASKYEEMYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAAGAFCLALKILDNGEWTPTLQHYLSYTEESLLPVMQHLAKNVVMVNQGLTKHMTVKNKYATSKHAKISTLPQLNSALVQDLAKAVAKVProteinLength(aa)433